NasdaqCM - Delayed Quote • USD
Exact Sciences Corporation (EXAS)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 4:39 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 16 | 16 | 18 | 17 |
| Avg. Estimate | -0.47 | -0.23 | -0.85 | 0.06 |
| Low Estimate | -0.63 | -0.34 | -1.29 | -0.64 |
| High Estimate | -0.17 | -0.09 | -0.31 | 0.81 |
| Year Ago EPS | -0.42 | -0.45 | -1.13 | -0.85 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 20 | 20 | 22 | 21 |
| Avg. Estimate | 627.36M | 700.15M | 2.83B | 3.23B |
| Low Estimate | 619.99M | 682M | 2.82B | 3.17B |
| High Estimate | 647M | 721.08M | 2.87B | 3.36B |
| Year Ago Sales | 602.45M | 622.09M | 2.5B | 2.83B |
| Sales Growth (year/est) | 4.10% | 12.50% | 13.30% | 13.90% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.75 | -0.51 | -0.48 | -0.46 |
| EPS Actual | -0.42 | -0.45 | 0 | -0.27 |
| Difference | 0.33 | 0.06 | 0.48 | 0.19 |
| Surprise % | 44.00% | 11.80% | 100.00% | 41.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.47 | -0.23 | -0.85 | 0.06 |
| 7 Days Ago | -0.46 | -0.23 | -0.84 | 0.06 |
| 30 Days Ago | -0.46 | -0.22 | -0.83 | 0.07 |
| 60 Days Ago | -0.37 | -0.25 | -0.99 | 0.09 |
| 90 Days Ago | -0.37 | -0.25 | -0.98 | 0 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 1 | 2 |
| Up Last 30 Days | -- | 1 | 1 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 3 | 1 | 2 | 1 |
Growth Estimates
| CURRENCY IN USD | EXAS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -11.90% | -- | -- | 1.60% |
| Next Qtr. | 48.90% | -- | -- | 10.50% |
| Current Year | 24.80% | -- | -- | 5.20% |
| Next Year | 107.10% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 98.50% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | Citigroup: Buy to Buy | 4/3/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 2/22/2024 |
| Upgrade | Benchmark: Hold to Buy | 1/2/2024 |
| Initiated | Guggenheim: Buy | 12/14/2023 |
| Initiated | Wolfe Research: Outperform | 12/13/2023 |
| Maintains | Goldman Sachs: Buy to Buy | 11/3/2023 |
Related Tickers
GH Guardant Health, Inc.
16.07
-3.60%
ILMN Illumina, Inc.
117.43
+0.63%
TWST Twist Bioscience Corporation
27.95
-1.45%
NTRA Natera, Inc.
85.28
-2.29%
MYGN Myriad Genetics, Inc.
18.50
-0.05%
DHR Danaher Corporation
235.51
-0.36%
TMO Thermo Fisher Scientific Inc.
544.78
+0.60%
WAT Waters Corporation
296.10
+0.64%
IDXX IDEXX Laboratories, Inc.
476.35
-0.30%
FLGT Fulgent Genetics, Inc.
20.36
+1.24%